| Amanda Bahr, MS, LMFT | |
|
1128 Westrac Dr S Ste A, Fargo, ND 58103-8729 | |
| (701) 561-1177 | |
| Not Available |
| Full Name | Amanda Bahr |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 1128 Westrac Dr S Ste A, Fargo, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154896314 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 3687 (Minnesota) | Secondary |
| 106H00000X | Marriage & Family Therapist | 2018-067 (North Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Bahr, MS, LMFT 1128 Westrac Dr S Ste A, Fargo, ND 58103-8729 Ph: (701) 561-1177 | Amanda Bahr, MS, LMFT 1128 Westrac Dr S Ste A, Fargo, ND 58103-8729 Ph: (701) 561-1177 |
News Archive
Researchers reporting in the February 3rd issue of Cell Metabolism may have a new way to trick the body into consuming more energy. The target in this case is an enzyme that indirectly controls the activity of what the researchers refer to as the "energy master switch." It boils down to this:
The study, published in the February issue of Stem Cells, outlines how researchers discovered that the jelly-like connective tissue surrounding the blood vessels of the human umbilical cord, the so-called "Wharton's Jelly," is rich in mesenchymal progenitor cells – cells that generate bone, cartilage and other tissues – and can be harvested to generate an abundant supply in a short amount of time.
AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research Annual Meeting in Washington, DC.
› Verified 5 days ago
Cynthia Johnson, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3309 Fiechtner Dr. S. Ste H, Fargo, ND 58103 Phone: 218-329-3552 Fax: 701-403-8003 | |
Clara A Erickson, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1330 Page Dr S, Ste 102a, Fargo, ND 58103 Phone: 701-446-6500 | |
Mrs. Heather Elaine Bjur, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1112 Nodak Dr S, Fargo, ND 58103 Phone: 701-232-6224 Fax: 701-232-4687 | |
William Noel Ahlfeldt, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 102 25th Ave N, Fargo, ND 58102 Phone: 701-412-6953 | |
Victoria Zak, Couples Therapy Medicare: Medicare Enrolled Practice Location: 1720 University Dr S, Fargo, ND 58103 Phone: 701-234-2000 | |
Mary K Uong-kaale, Couples Therapy Medicare: Medicare Enrolled Practice Location: 1201 25th St S, Fargo, ND 58103 Phone: 701-451-4900 |